By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Avaxia Biologics, Inc. 

26 Pemberton Rd.

Wayland  Massachusetts  01778  U.S.A.
Phone: n/a Fax: n/a


Company News
Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation For AVX-470 For The Treatment Of Pediatric Ulcerative Colitis 11/21/2014 10:37:21 AM
Avaxia Biologics, Inc. Reports That Lead Product AVX-470 Achieves Objectives In Phase 1b Clinical Trial In Ulcerative Colitis 5/2/2014 11:50:25 AM
Avaxia Biologics, Inc. Awarded Patent With Broad Coverage Over Oral Anti-TNF Antibodies For Inflammatory Bowel Disease 2/11/2014 11:03:59 AM
Avaxia Biologics, Inc. Appoints Kevin Sarney, CPA, as Vice President, Finance and Administration 10/3/2013 7:28:58 AM
AbbVie (ABBV) Jumps Into $11.4 Million Series B for Avaxia Biologics, Inc. 6/7/2013 7:15:47 AM
Avaxia Biologics, Inc. Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis 2/25/2013 11:09:30 AM
Avaxia Biologics, Inc. Raises $6.4 Million in Series B Financing 12/18/2012 6:44:10 AM
Avaxia Biologics, Inc. Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis 11/27/2012 8:29:47 AM
Avaxia Biologics, Inc. is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity 9/18/2012 10:15:25 AM
Avaxia Biologics, Inc. Announces Appointment of Michael D. Rivard as VP Corporate Development 6/13/2012 10:09:49 AM